Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rutgers

Showing results (741-750 of 982) with videos related to

Pageof 99
Sort By:
Breast Cancer Research and Treatment|January 29, 2016
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordanceGiuseppe Viale, Leen Slaets, Femke A de Snoo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 17, 2011
High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trialD B Y Fontein, J W R Nortier, G J Liefers, et al.
Annals of Nuclear Medicine|September 29, 2011
FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case seriesBas B Koolen, Erik Vegt, Emiel J Th Rutgers, et al.
Annals of Surgical Oncology|December 2, 2009
Lymphatic drainage patterns from the treated breastIris M C van der Ploeg, Hester S A Oldenburg, Emiel J T Rutgers, et al.
Breast Cancer Research and Treatment|December 11, 2012
Diffuse reflectance spectroscopy: towards clinical application in breast cancerDaniel J Evers, Rami Nachabe, Marie-Jeanne Vranken Peeters, et al.
Plos One|March 17, 2026
Is check-up on demand non-inferior to routine follow-up at one year after total hip or knee arthroplasty in terms of clinical outcomes and cost-effectiveness? Protocol for a randomized stepped-wedge hybrid effectiveness de-implementation trialAriena J Rasker, Lidy A C Roubos, Dominique C Baas, et al.
Human Pathology|September 28, 2015
Vascular invasion in uterine sarcomas and its significance. A multi-institutional studyAndres A Roma, Denise A Barbuto, Siavash Azadmanesh Samimi, et al.
Annals of Surgical Oncology|December 14, 2025
The Value of Ultrasound in Patients with T1-T2 Breast Cancer with No Palpable Lymph Nodes Enrolled in the EORTC 10981-22023 AMAROS TrialA W J Beerthuizen, T I M Snellen, S A Bartels, et al.
The American Journal of Pathology|April 23, 2017
miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from ApoptosisYe Yuan, Joost Kluiver, Jasper Koerts, et al.
Plos One|August 28, 2025
How do patients and health care professionals perceive de-implementation of routine follow-ups after total hip or knee arthroplasty? Protocol for a nested qualitative study within a hybrid effectiveness de-implementation trialLex D de Jong, Dominique C Baas, Lidy A C Roubos, et al.
Pageof 99

Showing results (741-750 of 982) with videos related to

Sort By:
Pageof 99
Breast Cancer Research and Treatment|January 29, 2016
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordanceGiuseppe Viale, Leen Slaets, Femke A de Snoo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 17, 2011
High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trialD B Y Fontein, J W R Nortier, G J Liefers, et al.
Annals of Nuclear Medicine|September 29, 2011
FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case seriesBas B Koolen, Erik Vegt, Emiel J Th Rutgers, et al.
Annals of Surgical Oncology|December 2, 2009
Lymphatic drainage patterns from the treated breastIris M C van der Ploeg, Hester S A Oldenburg, Emiel J T Rutgers, et al.
Breast Cancer Research and Treatment|December 11, 2012
Diffuse reflectance spectroscopy: towards clinical application in breast cancerDaniel J Evers, Rami Nachabe, Marie-Jeanne Vranken Peeters, et al.
Plos One|March 17, 2026
Is check-up on demand non-inferior to routine follow-up at one year after total hip or knee arthroplasty in terms of clinical outcomes and cost-effectiveness? Protocol for a randomized stepped-wedge hybrid effectiveness de-implementation trialAriena J Rasker, Lidy A C Roubos, Dominique C Baas, et al.
Human Pathology|September 28, 2015
Vascular invasion in uterine sarcomas and its significance. A multi-institutional studyAndres A Roma, Denise A Barbuto, Siavash Azadmanesh Samimi, et al.
Annals of Surgical Oncology|December 14, 2025
The Value of Ultrasound in Patients with T1-T2 Breast Cancer with No Palpable Lymph Nodes Enrolled in the EORTC 10981-22023 AMAROS TrialA W J Beerthuizen, T I M Snellen, S A Bartels, et al.
The American Journal of Pathology|April 23, 2017
miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from ApoptosisYe Yuan, Joost Kluiver, Jasper Koerts, et al.
Plos One|August 28, 2025
How do patients and health care professionals perceive de-implementation of routine follow-ups after total hip or knee arthroplasty? Protocol for a nested qualitative study within a hybrid effectiveness de-implementation trialLex D de Jong, Dominique C Baas, Lidy A C Roubos, et al.
Pageof 99